Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study

Stopped early

Conditions studied: Cardiovascular Disease

In brief

The primary objective of this trial is to demonstrate the non-inferiority of clopidogrel compared to prasugrel over 6 months in cardiovascular disease patients when the clopidogrel cohort is limited to the estimated 70% of the population that are CYP2C19 extensive metabolizers. This protocol will examine the comparative effectiveness of these two strategies.

Key facts

Study ID

NCT00995514

Run by

Medco Health Solutions, Inc.

People needed

4471

Starts

2009-10-01

Expected to finish

2012-05-01

Last updated by the study team

2012-05-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women between 18 years and 75 years of age
• Recent prescription for clopidogrel or prasugrel.
• Participant is willing and able to provide informed consent.

You may not qualify if…

• Previous use of any thienopyridine within 4 months of initiating new clopidogrel or prasugrel therapy.
• Participant refusal to participate in the study.
• Anticipated discontinuation of clopidogrel or prasugrel within the 6 month study follow-up period
• Participants that have previously stated "do not contact"

Where it is running

• Medco Health Solutions, Inc — Franklin Lakes, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.